S
Silvana Capalbo
Researcher at University of Bari
Publications - 56
Citations - 1207
Silvana Capalbo is an academic researcher from University of Bari. The author has contributed to research in topics: Chronic lymphocytic leukemia & Multiple myeloma. The author has an hindex of 17, co-authored 56 publications receiving 1011 citations. Previous affiliations of Silvana Capalbo include University of Foggia & Marche Polytechnic University.
Papers
More filters
Journal ArticleDOI
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction
Silvia Colucci,Giacomina Brunetti,Giacomina Brunetti,Rita Rizzi,Rita Rizzi,Antonia Zonno,Antonia Zonno,Giorgio Mori,Giorgio Mori,Graziana Colaianni,Graziana Colaianni,Davide Del Prete,Davide Del Prete,Roberta Faccio,Roberta Faccio,Arcangelo Liso,Arcangelo Liso,Silvana Capalbo,Silvana Capalbo,Vincenzo Liso,Vincenzo Liso,Alberta Zallone,Alberta Zallone,Maria Grano,Maria Grano +24 more
TL;DR: It is shown that MM T cells support OC formation and survival, possibly involving OPG/TRAIL interaction and unbalanced OC expression of TRAIL death and decoy receptors.
Journal ArticleDOI
Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia
Wilma Barcellini,Silvana Capalbo,Rosa Maria Agostinelli,Francesca Romana Mauro,Achille Ambrosetti,Rossella Calori,Agostino Cortelezzi,Luca Laurenti,Enrico Pogliani,Paola Pedotti,Vincenzo Liso,Gabriella Girelli,Franco Mandelli,Alberto Zanella +13 more
TL;DR: In this paper, a multicenter GIMEMA study was conducted to correlate autoimmune complications (AIC) in B-cell chronic lymphocytic leukemia (B-CLL) with stage and therapy.
Journal ArticleDOI
Rituximab therapy for chronic lymphocytic leukemia‐associated autoimmune hemolytic anemia
Giovanni D'Arena,Luca Laurenti,Silvana Capalbo,Alfonso Maria D'Arco,Rosaria De Filippi,Gianpaolo Marcacci,Nicola Di Renzo,Sergio Storti,Catello Califano,Maria Luigia Vigliotti,Michela Tarnani,Felicetto Ferrara,Antonio Pinto +12 more
TL;DR: The results prove that the anti‐CD20 monoclonal antibody rituximab is an effective and well‐tolerated alternative treatment for CLL‐associated AIHA.
Journal ArticleDOI
Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients.
Giovanni D'Arena,Catello Califano,Mario Annunziata,Alfredo Tartarone,Silvana Capalbo,Oreste Villani,Giovanni Amendola,Giuseppe Pietrantuono,Felicetto Ferrara,Antonio Pinto,Pellegrino Musto,A. D'Arco,Nicola Cascavilla +12 more
TL;DR: It is shown that anti‐CD20 monoclonal antibody rituximab is an effective and safe alternative treatment option for idiopathic AIHA, in particular, for steroid‐refractory disease.
Journal ArticleDOI
Lenalidomide Restrains Motility and Overangiogenic Potential of Bone Marrow Endothelial Cells in Patients with Active Multiple Myeloma
Annunziata De Luisi,Arianna Ferrucci,Addolorata Coluccia,Roberto Ria,Michele Moschetta,Emanuela de Luca,Luisa Pieroni,Michele Maffia,Andrea Urbani,Giulia Di Pietro,Attilio Guarini,Girolamo Ranieri,Paolo Ditonno,Simona Berardi,Antonella Caivano,Antonio Basile,Nicola Cascavilla,Silvana Capalbo,Giovanni Quarta,Franco Dammacco,Domenico Ribatti,Angelo Vacca +21 more
TL;DR: Information is provided on the molecular mechanisms associated with the antimigratory and antiangiogenic effects of lenalidomide in primary MMECs, thus giving new avenues for effective endothelium-targeted therapies in MM.